Trials / Withdrawn
WithdrawnNCT04467281
A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical Applications
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if using the radioactive tracer 89Zr-DFO-daratumumab with PET/CT scans is a practical and effective way to view and monitor multiple myeloma in participants before and during their treatment with daratumumab. We also want to see if 89Zr-DFO-daratumumab PET/CT scans can predict a participant's response to therapy, and if they can better locate any leftover disease following treatment compared to the standard imaging methods.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 89Zr-DFO-daratumumab | Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans. |
| DIAGNOSTIC_TEST | PET/CT | Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans. |
Timeline
- Start date
- 2020-06-30
- Primary completion
- 2021-02-26
- Completion
- 2021-02-26
- First posted
- 2020-07-13
- Last updated
- 2022-07-01
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04467281. Inclusion in this directory is not an endorsement.